Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1993;1(2):108–113. doi: 10.1155/S1064744993000250

Quinolones for the Treatment of Neisseria Gonorrhoeae and Chlamydia Trachomatis

Sebastian Faro 1,✉
PMCID: PMC2364295  PMID: 18475328

Abstract

The most commonly sexually transmitted bacteria are Neisseria gonorrhoeae and Chlamydia trachomatis. The quinolones ofloxacin and ciprofloxacin have been shown to have activity against both of these bacteria in vitro and in vivo. Ofloxacin is particularly well suited for the treatment of N. gonorrhoeae and C. trachomatis cervical infection, which can be considered the earliest manifestation of pelvic inflammatory disease (PID). Not only can ofloxacin be effectively used as a single agent, it is also useful in treating urinary tract infections caused by Enterobacteriaceae. Although it has moderate activity against anaerobes in general, ofloxacin does have activity against the anaerobes commonly isolated from female patients with soft tissue pelvic infections. Thus, ofloxacin has the potential for being utilized to treat early salpingitis.

Full Text

The Full Text of this article is available as a PDF (531.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Batteiger B. E., Jones R. B., White A. Efficacy and safety of ofloxacin in the treatment of nongonococcal sexually transmitted disease. Am J Med. 1989 Dec 29;87(6C):75S–77S. [PubMed] [Google Scholar]
  2. Bäckman M., Rudén A. K., Bygdeman S. M., Jonsson A., Ringertz O., Sandström E. G. Gonococcal serovar distribution in Stockholm, with special reference to multiple infections and infected partners. Acta Pathol Microbiol Immunol Scand B. 1985 Jun;93(3):225–232. doi: 10.1111/j.1699-0463.1985.tb02880.x. [DOI] [PubMed] [Google Scholar]
  3. Chaim W., Sarov B., Sarov I., Piura B., Cohen A., Insler V. Serum IgG and IgA antibodies to Chlamydia in ectopic pregnancies. Contraception. 1989 Jul;40(1):59–71. doi: 10.1016/0010-7824(89)90028-0. [DOI] [PubMed] [Google Scholar]
  4. Conway D., Glazener C. M., Caul E. O., Hodgson J., Hull M. G., Clarke S. K., Stirrat G. M. Chlamydial serology in fertile and infertile women. Lancet. 1984 Jan 28;1(8370):191–193. doi: 10.1016/s0140-6736(84)92113-5. [DOI] [PubMed] [Google Scholar]
  5. Cook T. M., Brown K. G., Boyle J. V., Goss W. A. Bactericidal action of nalidixic acid on Bacillus subtilis. J Bacteriol. 1966 Nov;92(5):1510–1514. doi: 10.1128/jb.92.5.1510-1514.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Covino J. M., Cummings M., Smith B., Benes S., Draft K., McCormack W. M. Comparison of ofloxacin and ceftriaxone in the treatment of uncomplicated gonorrhea caused by penicillinase-producing and non-penicillinase-producing strains. Antimicrob Agents Chemother. 1990 Jan;34(1):148–149. doi: 10.1128/aac.34.1.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cox C. E. Ofloxacin in the management of complicated urinary tract infections, including prostatitis. Am J Med. 1989 Dec 29;87(6C):61S–68S. [PubMed] [Google Scholar]
  8. Davis G. J., McKenzie B. E. Toxicologic evaluation of ofloxacin. Am J Med. 1989 Dec 29;87(6C):43S–46S. [PubMed] [Google Scholar]
  9. Delmee M., Avesani V. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 1986 Feb;29(2):374–375. doi: 10.1128/aac.29.2.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dodson M. G., Faro S., Gentry L. O. Treatment of acute pelvic inflammatory disease with aztreonam, a new monocyclic beta-lactam antibiotic, and clindamycin. Obstet Gynecol. 1986 May;67(5):657–662. doi: 10.1097/00006250-198605000-00010. [DOI] [PubMed] [Google Scholar]
  11. Edwards D. J., Bowles S. K., Svensson C. K., Rybak M. J. Inhibition of drug metabolism by quinolone antibiotics. Clin Pharmacokinet. 1988 Sep;15(3):194–204. doi: 10.2165/00003088-198815030-00004. [DOI] [PubMed] [Google Scholar]
  12. Faro S. Chlamydia trachomatis infection in women. J Reprod Med. 1985 Mar;30(3 Suppl):273–278. [PubMed] [Google Scholar]
  13. Flor S. Pharmacokinetics of ofloxacin. An overview. Am J Med. 1989 Dec 29;87(6C):24S–30S. [PubMed] [Google Scholar]
  14. Fuchs P. C., Barry A. L., Jones R. N., Thornsberry C. Proposed disk diffusion susceptibility criteria for ofloxacin. J Clin Microbiol. 1985 Aug;22(2):310–311. doi: 10.1128/jcm.22.2.310-311.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gellert M., Mizuuchi K., O'Dea M. H., Nash H. A. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A. 1976 Nov;73(11):3872–3876. doi: 10.1073/pnas.73.11.3872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gentry L. O., Rodriguez-Gomez G., Zeluff B. J., Khoshdel A., Price M. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med. 1989 Dec 29;87(6C):57S–60S. [PubMed] [Google Scholar]
  17. Grüneberg R. N., Felmingham D., O'Hare M. D., Robbins M. J., Perry K., Wall R. A., Ridgway G. L. The comparative in-vitro activity of ofloxacin. J Antimicrob Chemother. 1988 Sep;22 (Suppl 100):9–19. doi: 10.1093/jac/22.supplement_c.9. [DOI] [PubMed] [Google Scholar]
  18. King A., Phillips I. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. J Antimicrob Chemother. 1986 Nov;18 (Suppl 500):1–20. doi: 10.1093/jac/18.supplement_d.1. [DOI] [PubMed] [Google Scholar]
  19. Kirshon B., Faro S., Phillips L. E., Pruett K. Correlation of ultrasonography and bacteriology of the endocervix and posterior cul-de-sac of patients with severe pelvic inflammatory disease. Sex Transm Dis. 1988 Apr-Jun;15(2):103–107. doi: 10.1097/00007435-198804000-00007. [DOI] [PubMed] [Google Scholar]
  20. LESHER G. Y., FROELICH E. J., GRUETT M. D., BAILEY J. H., BRUNDAGE R. P. 1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. J Med Pharm Chem. 1962 Sep;91:1063–1065. doi: 10.1021/jm01240a021. [DOI] [PubMed] [Google Scholar]
  21. Lutz F. B., Jr Single-dose efficacy of ofloxacin in uncomplicated gonorrhea. Am J Med. 1989 Dec 29;87(6C):69S–74S. [PubMed] [Google Scholar]
  22. McCormack W. M., Rosner B., McComb D. E., Evrard J. R., Zinner S. H. Infection with Chlamydia trachomatis in female college students. Am J Epidemiol. 1985 Jan;121(1):107–115. doi: 10.1093/oxfordjournals.aje.a113971. [DOI] [PubMed] [Google Scholar]
  23. Paavonen J., Roberts P. L., Stevens C. E., Wølner-Hanssen P., Brunham R. C., Hillier S., Stamm W. E., Kuo C. C., DeRouen T., Holmes K. K. Randomized treatment of mucopurulent cervicitis with doxycycline or amoxicillin. Am J Obstet Gynecol. 1989 Jul;161(1):128–135. doi: 10.1016/0002-9378(89)90249-4. [DOI] [PubMed] [Google Scholar]
  24. Phillips R. S., Safran C., Aronson M. D., Taylor W. C. Should women be tested for gonococcal infection of the cervix during routine gynecologic visits? An economic appraisal. Am J Med. 1989 Mar;86(3):297–302. doi: 10.1016/0002-9343(89)90299-4. [DOI] [PubMed] [Google Scholar]
  25. Rice R. J., Thompson S. E. Treatment of uncomplicated infections due to Neisseria gonorrhoeae. A review of clinical efficacy and in vitro susceptibility studies from 1982 through 1985. JAMA. 1986 Apr 4;255(13):1739–1746. [PubMed] [Google Scholar]
  26. Schachter J., Moncada J. V. In vitro activity of ofloxacin against Chlamydia trachomatis. Am J Med. 1989 Dec 29;87(6C):14S–16S. [PubMed] [Google Scholar]
  27. Stocks J. M., Wallace R. J., Jr, Griffith D. E., Garcia J. G., Kohler R. B. Ofloxacin in community-acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. Am J Med. 1989 Dec 29;87(6C):52S–56S. [PubMed] [Google Scholar]
  28. Svensson L., Mårdh P. A., Weström L. Infertility after acute salpingitis with special reference to Chlamydia trachomatis. Fertil Steril. 1983 Sep;40(3):322–329. doi: 10.1016/s0015-0282(16)47294-8. [DOI] [PubMed] [Google Scholar]
  29. Van Caekenberghe D. L., Pattyn S. R. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother. 1984 Apr;25(4):518–521. doi: 10.1128/aac.25.4.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Washington A. E., Cates W., Jr, Zaidi A. A. Hospitalizations for pelvic inflammatory disease. Epidemiology and trends in the United States, 1975 to 1981. JAMA. 1984 May 18;251(19):2529–2533. doi: 10.1001/jama.251.19.2529. [DOI] [PubMed] [Google Scholar]
  31. Wijnands W. J., Vree T. B., van Herwaarden C. L. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol. 1986 Dec;22(6):677–683. doi: 10.1111/j.1365-2125.1986.tb02957.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES